Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/47747
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhou K. | - |
dc.contributor.author | Zou D. | - |
dc.contributor.author | Zhou J. | - |
dc.contributor.author | Hu J. | - |
dc.contributor.author | Yang H. | - |
dc.contributor.author | Zhang H. | - |
dc.contributor.author | Ji J. | - |
dc.contributor.author | Xu W. | - |
dc.contributor.author | Jin J. | - |
dc.contributor.author | Lv F. | - |
dc.contributor.author | Feng R. | - |
dc.contributor.author | Gao S. | - |
dc.contributor.author | Zhou D. | - |
dc.contributor.author | Tam C.S. | - |
dc.contributor.author | Simpson D. | - |
dc.contributor.author | Wang M. | - |
dc.contributor.author | Phillips T.J. | - |
dc.contributor.author | Opat S. | - |
dc.contributor.author | Huang Z. | - |
dc.contributor.author | Lu H. | - |
dc.contributor.author | Song Y. | - |
dc.date.accessioned | 2022-05-23T06:01:10Z | - |
dc.date.available | 2022-05-23T06:01:10Z | - |
dc.date.copyright | 2021 | - |
dc.date.issued | 2022-05-04 | en |
dc.identifier.citation | Journal of Hematology and Oncology. 14(1) (no pagination), 2021. Article Number: 167. Date of Publication: December 2021. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/47747 | - |
dc.description.abstract | Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a high initial response rate followed almost invariably by relapse. Here we report the pooled data from 2 studies, BGB-3111-AU-003 and BGB-3111-206, to explore the efficacy of zanubrutinib monotherapy in relapsed/refractory (R/R) MCL. A total of 112 patients were included. Median follow-up durations were 24.7 and 24.9 months for BGB-3111-AU-003 and BGB-3111-206, respectively. Overall response rate (ORR) and complete response (CR) rate were 84.8% and 62.5%, and median duration of response, progression-free survival (PFS) and overall survival (OS) were 24.9, 25.8 and 38.2 months, respectively. After weighting, the PFS (median: NE vs. 21.1 months, P = 0.235) and OS (median: NE vs. 38.2 months, P = 0.057) were similar but numerically better in the second-line than later-line group. Zanubrutinib was well-tolerated with treatment discontinuation and dose reduction for adverse events in 12.5% and 2.7% of patients, respectively. Hypertension, major hemorrhage and atrial fibrillation/flutter rates were 11.6%, 5.4% and 1.8%, respectively. Zanubrutinib is efficacious in R/R MCL, with a favorable safety profile.Copyright © 2021, The Author(s). | - |
dc.publisher | BioMed Central Ltd | - |
dc.relation.ispartof | Journal of Hematology and Oncology | - |
dc.subject.mesh | atrial fibrillation autologous stem cell transplantation | - |
dc.subject.mesh | brain hemorrhage cancer patient | - |
dc.subject.mesh | congestive heart failure drug dose reduction | - |
dc.subject.mesh | drug efficacy | - |
dc.subject.mesh | drug safety | - |
dc.subject.mesh | drug tolerability | - |
dc.subject.mesh | drug withdrawal | - |
dc.subject.mesh | heart atrium flutter hypertension ischemic stroke mantle cell lymphoma | - |
dc.subject.mesh | mantle cell lymphoma | - |
dc.subject.mesh | monotherapy | - |
dc.subject.mesh | pneumonia progression free survival | - |
dc.subject.mesh | traffic accident | - |
dc.subject.mesh | bendamustine | - |
dc.subject.mesh | cyclophosphamide | - |
dc.subject.mesh | dexamethasone | - |
dc.subject.mesh | doxorubicin | - |
dc.subject.mesh | lenalidomide | - |
dc.subject.mesh | vincristine | - |
dc.subject.mesh | zanubrutinib | - |
dc.title | Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. | - |
dc.type | Letter | - |
dc.type.studyortrial | Opinion, perspective or news | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1186/s13045-021-01174-3 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.pubmedid | 34649571 [https://www.ncbi.nlm.nih.gov/pubmed/?term=34649571] | - |
dc.identifier.institution | (Zhou, Song) Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China | - |
dc.identifier.institution | (Zou) Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China | - |
dc.identifier.institution | (Zhou) Tongji Hospital, Tongji Medical College, Wuhan 430032, China | - |
dc.identifier.institution | (Hu) Fujian Medical University Union Hospital, Fuzhou 35000, China | - |
dc.identifier.institution | (Yang) Zhejiang Cancer Hospital, Hangzhou 310000, China | - |
dc.identifier.institution | (Zhang) Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China | - |
dc.identifier.institution | (Ji) West China Hospital of Sichuan University, Chengdu 610041, China | - |
dc.identifier.institution | (Xu) The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China | - |
dc.identifier.institution | (Jin) The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310003, China | - |
dc.identifier.institution | (Lv) Fudan University Shanghai Cancer Center, Shanghai 200032, China | - |
dc.identifier.institution | (Feng) Nanfang Hospital of Southern Medical University, Guangzhou 510515, China | - |
dc.identifier.institution | (Gao) The First Hospital of Jilin University, Changchun 130031, China | - |
dc.identifier.institution | (Zhou) Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China | - |
dc.identifier.institution | (Tam) Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC 3065, Australia | - |
dc.identifier.institution | (Simpson) North Shore Hospital, Auckland 2065, New Zealand | - |
dc.identifier.institution | (Wang) The University of Texas MD Anderson Cancer Center, Houston, TX 78701, United States | - |
dc.identifier.institution | (Phillips) University of Michigan, Ann Arbor, MI 48109, United States | - |
dc.identifier.institution | (Opat) Monash Health, Monash University, Clayton, VIC 3800, Australia | - |
dc.identifier.institution | (Huang, Lu) BeiGene (Beijing) Co., Ltd, Beijing 102206, China | - |
dc.identifier.institution | (Song) Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China | - |
dc.identifier.affiliationmh | (Opat) Monash Health, Monash University, Clayton, VIC 3800, Australia | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairetype | Letter | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.